Deals > All

France Monaco Central France Eastern France Northern France Paris (region) Southern France Western France

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1963 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Deal: Collaboration or Financing	Date
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED	2021-01-11
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies	2021-01-07
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare	2021-01-05
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare	2021-01-05
Cellectis–SEVERAL: investment, 202012 underwritten public offering of ADSs $100m+15m ANNOUNCED + WITHDRAWN	2020-12-14
InnoSkel–Consilium: public relations, 202012 service existent by Consilium Strategic Communications	2020-12-14
InnoSkel–Jeito Capital: investment, 202012 financing round Series A totalling €20m incl co-lead investor Jeito Capital	2020-12-14
InnoSkel–Région Sud (FR): investment, 202012 financing round Series A totalling €20m incl co-investor Région Sud Investissement	2020-12-14
InnoSkel–SEVERAL: investment, 202012 financing round Series A €20m co-led by Jeito Capital + Vida Ventures	2020-12-14
InnoSkel–Turenne: investment, 202012 financing round Series A totalling €20m incl co-investor The Turenne Group	2020-12-14
InnoSkel–Vida Ventures: investment, 202012 financing round Series A totalling €20m incl co-lead investor Vida Ventures	2020-12-14
MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management	2020-12-01
MaaT Pharma–France (govt): investment, 202012 financing round Series B extension totalling €7.35m incl new + lead investor PSIM Fund	2020-12-01
MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m	2020-12-01
MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science	2020-12-01
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED	2020-12-01
Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF	2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF	2020-11-25
AlgoTherapeutix–SEVERAL: investment, 202011 financing round Series A €12m led by Bpifrance InnoBio 2 fund + co-investor Omnes	2020-11-24
Catamaran Bio–SEVERAL: investment, 202011 financing round Series A $42m co-led by Sofinnova Partners + Lightstone Ventures	2020-11-23
Catamaran Bio–Sofinnova: investment, 202011 financing round Series A $42m incl co-lead investor Sofinnova Partners	2020-11-23
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund	2020-11-23
Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo	2020-11-23
Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund	2020-11-23
Myricx Pharma–SEVERAL: investment, 202011 seed financing round £4.5m with Sofinnova Partners + Brandon Capital Partners	2020-11-16
Myricx Pharma–Sofinnova: investment, 202011 seed financing round totalling £4.5m incl investor Sofinnova Partners	2020-11-16
Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi	2020-11-13
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV	2020-11-12
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings	2020-11-03
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures	2020-11-02
Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington	2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct)	2020-11-02
GenSight Biologics–Arix Bioscience: investment, 202010 private placement totalling €25m incl co-lead investor Arix Bioscience	2020-10-22
GenSight Biologics–France (govt): investment, 202010 private placement totalling €25m incl €1m from existing + co-investor Bpifrance Investissement	2020-10-22
GenSight Biologics–Invus Group: investment, 202010 private placement totalling €25m incl co-lead investor Invus	2020-10-22
GenSight Biologics–SEVERAL: investment, 202010 private placement €25m led by Arix Bioscience + Invus + Sofinnova Partners	2020-10-22
GenSight Biologics–Sofinnova: investment, 202010 private placement totalling €25m incl €4.5m from existing + co-lead investor Sofinnova Partners	2020-10-22
SparingVision–4BIO Ventures: investment, 202010 financing round totalling €44.5m incl new + co-lead investor 4BIO Capital	2020-10-21
SparingVision–Consilium: public relations, 202011 service existent by Consilium Strategic Communications	2020-10-21
SparingVision–Foundation Fighting Blindness: investment, 202010 financing round totalling €44.5m incl existing + co-investor FFB	2020-10-21
SparingVision–France (govt): investment, 202010 financing round totalling €44.5m incl existing + co-investor Bpifrance	2020-10-21
SparingVision–Jeito Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Jeito Capital	2020-10-21
SparingVision–SEVERAL: investment, 202010 financing round €44.5m led by 4BIO Capital + UPMC Enterprises	2020-10-21
SparingVision–Torreya: financial services, 202010 supply service Torreya Capital LLC acted as excl placement agent for €44.5m offering	2020-10-21
SparingVision–Univ Pittsburgh: investment, 202010 financing round totalling €44.5m incl new + co-lead investor UPMC Enterprises	2020-10-21
SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital	2020-10-21
Carmat–France (govt): grant, 202010– grant €13m national innovation funding for clinical study of artificial heart in France from Health Ministry	2020-10-12
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital	2020-10-12
Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP	2020-10-12
Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson	2020-10-12
Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd	2020-10-12
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap	2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners	2020-10-12
Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC	2020-10-12
Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital	2020-10-06
Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude	2020-10-06
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis	2020-10-06
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED	2020-10-02
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth	2020-10-01
Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2)	2020-09-29
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures	2020-09-25
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund	2020-09-23
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures	2020-09-17
ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m	2020-09-15
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020	2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital	2020-09-14
Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona	2020-09-14
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares	2020-08-19
Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share	2020-08-17
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED	2020-08-13
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital	2020-08-06
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital	2020-07-29
Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures	2020-07-28
Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners	2020-07-28
Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners	2020-07-21
Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF	2020-07-21
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina	2020-07-14
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications	2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties	2020-07-08
Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund	2020-07-02
Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures	2020-07-02
Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases	2020-07-01
Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck	2020-07-01
Enterome–BPCE: investment, 202006 financing round Series E €na incl existing investor Seventure Health for Life Capital	2020-06-25
Enterome–Nestlé: investment, 202006 financing round Series E €na incl existing investor Nestlé Health Science	2020-06-25
Enterome–Omnes Capital: investment, 202006 financing round Series E €na incl existing investor Omnes Capital	2020-06-25
Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia	2020-06-25
Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma	2020-06-25
Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC	2020-06-25
Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd	2020-06-25
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion	2020-06-22
Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m led by Optum Ventures + Idinvest + capital300	2020-06-18
DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology	2020-06-16
DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA	2020-06-16
DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF	2020-06-16
DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund	2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund	2020-06-16
eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity	2020-06-16
MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors	2020-06-16
Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2	2020-06-16

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)